Showing results (251-260 of 295) with videos related to

Sort By:
Pageof 30
Cancer Discovery|February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid TumorsEric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical TrialAbdulazeez Salawu, Ben X Wang, Ming Han, et al.
JAMA Oncology|September 28, 2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled TrialTae Won Kim, Philippe L Bedard, Patricia LoRusso, et al.
JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.
International Journal of Cancer|September 6, 2012
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trialBen Tran, Andrew M K Brown, Philippe L Bedard, et al.
Clinical Colorectal Cancer|July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic CancerAlberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
JAMA Oncology|December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical TrialNancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Cancer Research|October 29, 2021
Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune ResponseNisha Kanwar, Zaldy Balde, Ranju Nair, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumorsKirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.
JCO Precision Oncology|August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-BPhilippe L Bedard, Shuli Li, Kari B Wisinski, et al.
Pageof 30